Gain Therapeutics(GANX)
BETHESDA, MDBiotechnology
Focus: Gain Therapeutics is a public biotech company focused on Site-directed Enzyme Enhancement Therapy (SDET) for neurology and metabolic diseases. The company is early-stage with minimal revenue and is in the discovery-to-Phase 2 development phase.
Profile data last refreshed 2h ago · AI intelligence enriched 2mo ago
Funding Stage
PUBLIC
Total Funding
$300M
Open Jobs
14+3 this month
Stable — net +3 jobs in 30d
4 added, 1 removed. Backfill posture.
Should You Work at Gain Therapeutics?
AI assessmentHigh-risk, high-reward opportunity best suited for scientists prioritizing early-stage platform potential over near-term job security or stability.
Why Work Here
- Ground-floor opportunity at a novel platform company with differentiated SDET technology focused on high-value indications (Parkinson's disease, Type 2 diabetes)
- Public company status provides liquidity and institutional credibility despite early pipeline stage
Data completeness
5/9 — Partial
Company HealthStrong
Pipeline
Early-stage
4 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$55K
Pipeline & Clinical Trials
Envita Stories Methodology in Long-term care Centres for old adults
Long-term Care Centres for Old Adults UsersClinical Trials (1)
NCT06569628Validation of a Life Stories Methodologies in Long-Term Care Centres
N/AHelp build intelligence for Gain Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.